Form 4: Heron Therapeutics Insider Sells Shares

Heron Therapeutics Chief Operating Officer Mark Hensley reported a transaction involving 11,770 shares of common stock.

Summary

• Mark Hensley, Chief Operating Officer of Heron Therapeutics, Inc., reported a transaction on April 30, 2026.
• The transaction involved the disposal of 11,770 shares of common stock.
• Hensley also holds 176,545 restricted stock units (RSUs) as of the reporting date.
• These RSUs vest in 16 equal quarterly installments starting one quarter after the grant date of January 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing as it reports a standard insider transaction without providing additional strategic or financial context.

Negatives

• Insider selling activity can sometimes be interpreted negatively by the market, although the specific reasons for the sale are not detailed in this filing.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. While this filing indicates a sale by a key executive, it does not provide context on the strategic implications for Heron Therapeutics within the broader biopharmaceutical industry.

Stakeholder Impact

• Shareholders may observe this transaction as a signal from management, though the specific intent behind the sale is not disclosed.

Key Dates

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, COO